Last reviewed · How we verify
Glycerophosphocholine (glycerylphosphorylcholine)
Glycerophosphocholine (generic name: glycerylphosphorylcholine) is a glycerylphosphorylcholine drug. It is currently in unknown development.
Glycerophosphocholine is thought to work by increasing the levels of a neurotransmitter called acetylcholine in the brain, which helps to protect neurons from damage.
Glycerophosphocholine, also known as glycerylphosphorylcholine, is a small molecule drug in the glycerylphosphorylcholine class. Its exact mechanism of action and target are unknown, but it is believed to have neuroprotective properties. The commercial status of glycerophosphocholine is unclear, and it is not FDA-approved for any indications. Further research is needed to fully understand its safety and efficacy. As a result, it is not widely available or prescribed.
At a glance
| Generic name | glycerylphosphorylcholine |
|---|---|
| Drug class | glycerylphosphorylcholine |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain's neurons as a busy city with many messengers running around. Acetylcholine is one of these messengers that helps keep the city running smoothly. Glycerophosphocholine is thought to help increase the production of acetylcholine, which can help protect the city from damage and keep it running efficiently.
Approved indications
Common side effects
Key clinical trials
- The Acute Effects of Onnit Alpha Brain on Cognition and Mood States (NA)
- Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance. (NA)
- Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules (NA)
- The Effect of α-GPC on Cognitive Function and Sports Performance (NA)
- Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers (PHASE1)
- Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease (PHASE4)
- Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults (PHASE1)
- Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycerophosphocholine CI brief — competitive landscape report
- Glycerophosphocholine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Glycerophosphocholine
What is Glycerophosphocholine?
How does Glycerophosphocholine work?
What is the generic name of Glycerophosphocholine?
What drug class is Glycerophosphocholine in?
What development phase is Glycerophosphocholine in?
Related
- Drug class: All glycerylphosphorylcholine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing